NICOLE FLEMING

TitleAssistant Professor
InstitutionMD Anderson
DepartmentGynecological Oncology & Reproductive Medicine
Address1155 Pressler St
Houston TX 77030-3721
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Knisely A, Iniesta MD, Batman S, Meyer LA, Soliman PT, Cain KE, Marten C, Chisholm G, Schmeler KM, Taylor JS, Fleming ND. Efficacy, safety, and feasibility of Apixaban for postoperative venous thromboembolism prophylaxis following open gynecologic cancer surgery at a comprehensive cancer center. Gynecol Oncol. 2024 Feb 16. PMID: 38368180.
      Citations:    Fields:    
    2. Hinchcliff EM, Knisely A, Adjei N, Fellman B, Yuan Y, Patel A, Xu C, Westin SN, Sood AK, Soliman PT, Shafer A, Fleming ND, Gershenson DM, Vikram R, Bathala T, Vining D, Ganeshan DM, Lu KH, Sun CC, Meyer LA, Jazaeri AA. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer. Cancer. 2024 04 01; 130(7):1061-1071. PMID: 38009662.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    3. Corvigno S, Badal S, Spradlin ML, Keating M, Pereira I, Stur E, Bayraktar E, Foster KI, Bateman NW, Barakat W, Darcy KM, Conrads TP, Maxwell GL, Lorenzi PL, Lutgendorf SK, Wen Y, Zhao L, Thaker PH, Goodheart MJ, Liu J, Fleming N, Lee S, Eberlin LS, Sood AK. In situ profiling reveals metabolic alterations in the tumor microenvironment of ovarian cancer after chemotherapy. NPJ Precis Oncol. 2023 Nov 03; 7(1):115. PMID: 37923835; PMCID: PMC10624842.
      Citations:    
    4. Foster KI, Handley KF, Glassman D, Sims TT, Javadi S, Palmquist SM, Saleh MM, Fellman BM, Fleming ND, Bhosale PR, Sood AK. Characterizing morphologic subtypes of high-grade serous ovarian cancer by CT: a retrospective cohort study. Int J Gynecol Cancer. 2023 06 05; 33(6):937-943. PMID: 36948527.
      Citations:    Fields:    Translation:Humans
    5. Foster KI, Shaw KRM, Jin J, Westin SN, Yap TA, Glassman DM, Jazaeri AA, Rauh-Hain JA, Lee S, Fellman BM, Ju Z, Liu Y, Fleming ND, Sood AK. Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer. Cancer. 2023 06 01; 129(11):1672-1680. PMID: 36930815.
      Citations:    Fields:    Translation:Humans
    6. Ludford K, Ho WJ, Thomas JV, Raghav KPS, Murphy MB, Fleming ND, Lee MS, Smaglo BG, You YN, Tillman MM, Kamiya-Matsuoka C, Thirumurthi S, Messick C, Johnson B, Vilar E, Dasari A, Shin S, Hernandez A, Yuan X, Yang H, Foo WC, Qiao W, Maru D, Kopetz S, Overman MJ. Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors. J Clin Oncol. 2023 04 20; 41(12):2181-2190. PMID: 36623241; PMCID: PMC10489404.
      Citations: 15     Fields:    Translation:HumansCellsCTClinical Trials
    7. Batman S, Messick CA, Milbourne A, Guo M, Munsell MF, Fokom-Domgue J, Salcedo M, Deshmukh A, Dahlstrom KR, Ogburn M, Price A, Fleming ND, Taylor J, Shafer A, Cobb L, Sigel K, Sturgis EM, Chiao EY, Schmeler KM. A Cross-Sectional Study of the Prevalence of Anal Dysplasia among Women with High-Grade Cervical, Vaginal, and Vulvar Dysplasia or Cancer: The PANDA Study. Cancer Epidemiol Biomarkers Prev. 2022 12 05; 31(12):2185-2191. PMID: 36126275; PMCID: PMC9729427.
      Citations:    
    8. Hinchcliff E, Rumpf J, Ratan R, Fleming ND, Jazaeri A, Fellman B, Meyer L, Soliman P. Hormone receptor status and the role of oophorectomy in uterine leiomyosarcoma. Gynecol Oncol. 2022 Oct 18. PMID: 36270831.
      Citations: 1     Fields:    
    9. Handley KF, Sims TT, Bateman NW, Glassman D, Foster KI, Lee S, Yao J, Yao H, Fellman BM, Liu J, Lu Z, Conrads KA, Hood BL, Barakat W, Zhao L, Zhang J, Westin SN, Celestino J, Rangel KM, Badal S, Pereira I, Ram PT, Maxwell GL, Eberlin LS, Futreal PA, Bast RC, Fleming ND, Conrads TP, Sood AK. Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics. JAMA Netw Open. 2022 10 03; 5(10):e2236626. PMID: 36239936; PMCID: PMC9568802.
      Citations: 2     Fields:    Translation:HumansCells
    10. Huepenbecker SP, Sun CC, Fu S, Zhao H, Primm K, Rauh-Hain JA, Fleming ND, Giordano SH, Meyer LA. Association between time to diagnosis, time to treatment, and ovarian cancer survival in the United States. Int J Gynecol Cancer. 2022 09 06; 32(9):1153-1163. PMID: 36166208; PMCID: PMC10410715.
      Citations:    Fields:    Translation:Humans
    11. Zhao L, Corvigno S, Ma S, Celestino J, Fleming ND, Hajek RA, Lankenau Ahumada A, Jennings NB, Thompson EJ, Tang H, Westin SN, Jazaeri AA, Zhang J, Futreal PA, Sood AK, Lee S. Molecular Profiles of Serum-Derived Extracellular Vesicles in High-Grade Serous Ovarian Cancer. Cancers (Basel). 2022 Jul 23; 14(15). PMID: 35892848; PMCID: PMC9330879.
      Citations:    
    12. Handley KF, Sood AK, Molin GZD, Westin SN, Meyer LA, Fellman B, Soliman PT, Coleman RL, Fleming ND. Frailty repels the knife: The impact of frailty index on surgical intervention and outcomes. Gynecol Oncol. 2022 07; 166(1):50-56. PMID: 35599168.
      Citations:    Fields:    Translation:Humans
    13. Glassman D, Bateman NW, Lee S, Zhao L, Yao J, Tan Y, Ivan C, Rangel KM, Zhang J, Conrads KA, Hood BL, Abulez T, Futreal PA, Fleming ND, Afshar-Kharghan V, Maxwell GL, Conrads TP, Chen K, Sood AK. Molecular Correlates of Venous Thromboembolism (VTE) in Ovarian Cancer. Cancers (Basel). 2022 Mar 15; 14(6). PMID: 35326647; PMCID: PMC8946269.
      Citations:    
    14. LaFargue CJ, Handley KF, Fleming ND, Nick AM, Chelariu-Raicu A, Fellman B, Castellano T, Ogasawara A, Hom-Tedla M, Blake EA, da Costa AABA, Crim AK, Rauh-Hain A, Westin SN, Coleman RL, Matsuo K, Baiocchi G, Hasegawa K, Moore K, Sood AK. Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer. Gynecol Oncol. 2022 04; 165(1):82-89. PMID: 35216808; PMCID: PMC8969169.
      Citations:    Fields:    Translation:Humans
    15. Corvigno S, Burks JK, Hu W, Zhong Y, Jennings NB, Fleming ND, Westin SN, Fellman B, Liu J, Sood AK. Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status. J Cancer Res Clin Oncol. 2021 Dec; 147(12):3545-3555. PMID: 34476576; PMCID: PMC8557133.
      Citations: 2     Fields:    Translation:HumansCells
    16. How JA, Patel S, Fellman B, Lu KH, Hwu P, Ramondetta LM, Westin SN, Fleming ND, Soliman PT, Jazaeri AA. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. Gynecol Oncol. 2021 07; 162(1):24-31. PMID: 33958211; PMCID: PMC8222164.
      Citations: 3     Fields:    Translation:Humans
    17. Nitecki R, Fleming ND, Fellman BM, Meyer LA, Sood AK, Lu KH, Rauh-Hain JA. Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol. 2021 06; 161(3):660-667. PMID: 33867146; PMCID: PMC8165031.
      Citations:    Fields:    Translation:Humans
    18. Fleming ND, Westin SN, Rauh-Hain JA, Soliman PT, Fellman BM, Coleman RL, Meyer LA, Shafer A, Cobb LP, Jazaeri A, Lu KH, Sood AK. Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. Gynecol Oncol. 2021 07; 162(1):65-71. PMID: 33838925; PMCID: PMC8287765.
      Citations: 1     Fields:    Translation:Humans
    19. How JA, Jazaeri AA, Soliman PT, Fleming ND, Gong J, Piha-Paul SA, Janku F, Stephen B, Naing A. Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial. Sci Rep. 2021 02 11; 11(1):3667. PMID: 33574401; PMCID: PMC7878854.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    20. Zhong Y, Liu J, Li X, Westin SN, Malpica A, Lawson BC, Lee S, Fellman BM, Coleman RL, Sood AK, Fleming ND. A Modified 2 Tier Chemotherapy Response Score (CRS) and Other Histopathologic Features for Predicting Outcomes of Patients with Advanced Extrauterine High-Grade Serous Carcinoma after Neoadjuvant Chemotherapy. Cancers (Basel). 2021 Feb 09; 13(4). PMID: 33572451; PMCID: PMC7916221.
      Citations: 2     
    21. Patel A, Iyer P, Matsuzaki S, Matsuo K, Sood AK, Fleming ND. Emerging Trends in Neoadjuvant Chemotherapy for Ovarian Cancer. Cancers (Basel). 2021 Feb 05; 13(4). PMID: 33562443; PMCID: PMC7915369.
      Citations: 3     
    22. Harrison RF, Cantor SB, Sun CC, Villanueva M, Westin SN, Fleming ND, Toumazis I, Sood AK, Lu KH, Meyer LA. Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer. Gynecol Oncol. 2021 04; 161(1):56-62. PMID: 33536126; PMCID: PMC8247119.
      Citations:    Fields:    Translation:Humans
    23. Lee S, Zhao L, Little LD, Westin SN, Jazarei AA, Fleming ND, Zhang J, Futreal PA, Sood AK. Distinct T?cell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroups. iScience. 2021 Feb 19; 24(2):102053. PMID: 33537658; PMCID: PMC7840469.
      Citations: 2     
    24. Fisher JG, Tait D, Garrett-Mayer E, Halabi S, Mangat PK, Schink JC, Alvarez RH, Veljovich D, Cannon TL, Crilley PA, Pollock T, Calfa CJ, Al Baghdadi T, Thota R, Fleming N, Cotta JA, Rygiel AL, Warren SL, Schilsky RL. Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 12; 15(6):733-741. PMID: 33090333.
      Citations: 4     Fields:    Translation:Humans
    25. Fleming ND, Westin SN, Meyer LA, Shafer A, Rauh-Hain JA, Onstad M, Cobb L, Bevers M, Fellman BM, Burzawa J, Bhosale P, Zand B, Jazaeri A, Levenback C, Coleman RL, Soliman PT, Sood AK. Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. Int J Gynecol Cancer. 2021 01; 31(1):92-97. PMID: 33154095; PMCID: PMC8266398.
      Citations: 1     Fields:    Translation:Humans
    26. Bailey CD, Previs R, Fellman BM, Zaid T, Huang M, Brown A, Enbaya A, Balakrishnan N, Broaddus RR, Bodurka DC, Soliman P, Fleming ND, Nick A, Sood AK, Westin SN. Pathologic distribution at the time of interval tumor reductive surgery informs personalized surgery for high-grade ovarian cancer. Int J Gynecol Cancer. 2021 02; 31(2):232-237. PMID: 33122243; PMCID: PMC8263077.
      Citations:    Fields:    Translation:Humans
    27. Westin SN, Fellman B, Sun CC, Broaddus RR, Woodall ML, Pal N, Urbauer DL, Ramondetta LM, Schmeler KM, Soliman PT, Fleming ND, Burzawa JK, Nick AM, Milbourne AM, Yuan Y, Lu KH, Bodurka DC, Coleman RL, Yates MS. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021 02; 224(2):191.e1-191.e15. PMID: 32805208; PMCID: PMC7855308.
      Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
    28. Cobb LP, Sun CC, Iyer R, Nick AM, Fleming ND, Westin SN, Sood AK, Wong KK, Silva EG, Gershenson DM. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. Gynecol Oncol. 2020 09; 158(3):653-658. PMID: 32709538.
      Citations: 4     Fields:    Translation:Humans
    29. Lee S, Zhao L, Rojas C, Bateman NW, Yao H, Lara OD, Celestino J, Morgan MB, Nguyen TV, Conrads KA, Rangel KM, Dood RL, Hajek RA, Fawcett GL, Chu RA, Wilson K, Loffredo JL, Viollet C, Jazaeri AA, Dalgard CL, Mao X, Song X, Zhou M, Hood BL, Banskota N, Wilkerson MD, Te J, Soltis AR, Roman K, Dunn A, Cordover D, Eterovic AK, Liu J, Burks JK, Baggerly KA, Fleming ND, Lu KH, Westin SN, Coleman RL, Mills GB, Casablanca Y, Zhang J, Conrads TP, Maxwell GL, Futreal PA, Sood AK. Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. Cell Rep. 2020 04 14; 31(2):107502. PMID: 32294438; PMCID: PMC7234854.
      Citations: 26     Fields:    Translation:Humans
    30. Lawson BC, Euscher ED, Bassett RL, Liu J, Ramalingam P, Zhong Y, Fleming ND, Malpica A. A 3-Tier Chemotherapy Response Score for Ovarian/Fallopian Tube/Peritoneal High-grade Serous Carcinoma: Is it Clinically Relevant? Am J Surg Pathol. 2020 02; 44(2):206-213. PMID: 31651523; PMCID: PMC6954274.
      Citations: 5     Fields:    Translation:Humans
    31. Stewart KI, Eska JS, Harrison RF, Suidan R, Abraham A, Chisholm GB, Meyer LA, Westin SN, Fleming ND, Frumovitz M, Aloia TA, Soliman PT. Implementation of a sentinel lymph node mapping algorithm for endometrial cancer: surgical outcomes and hospital charges. Int J Gynecol Cancer. 2020 03; 30(3):352-357. PMID: 31911539; PMCID: PMC7322720.
      Citations: 4     Fields:    Translation:Humans
    32. Lara OD, Krishnan S, Wang Z, Corvigno S, Zhong Y, Lyons Y, Dood R, Hu W, Qi L, Liu J, Coleman RL, Westin SN, Fleming ND, Cristini V, Rao A, Burks J, Sood AK. Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma. Sci Rep. 2019 11 26; 9(1):17589. PMID: 31772388; PMCID: PMC6879510.
      Citations: 5     Fields:    Translation:HumansCells
    33. Ramondetta LM, Hu W, Thaker PH, Urbauer DL, Chisholm GB, Westin SN, Sun Y, Ramirez PT, Fleming N, Sahai SK, Nick AM, Arevalo JMG, Dizon T, Coleman RL, Cole SW, Sood AK. Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression. Gynecol Oncol. 2019 09; 154(3):524-530. PMID: 31353053; PMCID: PMC6867685.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    34. Stewart KI, Chasen B, Erwin W, Fleming N, Westin SN, Dioun S, Frumovitz M, Ramirez PT, Lu KH, Wong F, Aloia TA, Soliman PT. Preoperative PET/CT does not accurately detect extrauterine disease in patients with newly diagnosed high-risk endometrial cancer: A prospective study. Cancer. 2019 10 01; 125(19):3347-3353. PMID: 31225906; PMCID: PMC6744337.
      Citations: 3     Fields:    Translation:Humans
    35. Armbruster SD, Previs R, Soliman PT, Westin SN, Fellman B, Jhingran A, Fleming ND. Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience. Gynecol Oncol. 2019 08; 154(2):328-332. PMID: 31221496; PMCID: PMC6822694.
      Citations: 2     Fields:    Translation:Humans
    36. Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, Westin SN. Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget. 2019 May 28; 10(37):3533-3546. PMID: 31191824; PMCID: PMC6544405.
      Citations: 10     Fields:    
    37. Ning MS, Dean MK, Taylor KA, Arzu I, Fleming ND, Mutyala N, Suresh P, Lewis MA, Tu J, Hassid VJ, Joe T, Byler C, Bloom ES, Shah S. Evaluation and Improvement of Bottlenecking in a Multidisciplinary Oncology Clinic: An Electronic Medical Record Intervention. Cureus. 2019 May 02; 11(5):e4583. PMID: 31309008; PMCID: PMC6609293.
      Citations:    
    38. Shah JS, Jooya ND, Woodard TL, Ramirez PT, Fleming ND, Frumovitz M. Reproductive counseling and pregnancy outcomes after radical trachelectomy for early stage cervical cancer. J Gynecol Oncol. 2019 May; 30(3):e45. PMID: 30887762; PMCID: PMC6424852.
      Citations: 6     Fields:    Translation:Humans
    39. Suidan RS, He W, Sun CC, Zhao H, Rauh-Hain JA, Fleming ND, Lu KH, Giordano SH, Meyer LA. Total and out-of-pocket costs of different primary management strategies in ovarian cancer. Am J Obstet Gynecol. 2019 08; 221(2):136.e1-136.e9. PMID: 30965052; PMCID: PMC7392324.
      Citations: 11     Fields:    Translation:Humans
    40. Suidan RS, He W, Sun CC, Zhao H, Smith GL, Klopp AH, Fleming ND, Lu KH, Giordano SH, Meyer LA. National trends, outcomes, and costs of radiation therapy in the management of low- and high-intermediate risk endometrial cancer. Gynecol Oncol. 2019 03; 152(3):439-444. PMID: 30876486; PMCID: PMC6662191.
      Citations: 2     Fields:    Translation:Humans
    41. Kurnit KC, Previs RA, Soliman PT, Westin SN, Klopp AH, Fellman BM, Lu KH, Ramondetta LM, Fleming ND. Prognostic factors impacting survival in early stage uterine carcinosarcoma. Gynecol Oncol. 2019 01; 152(1):31-37. PMID: 30414738; PMCID: PMC6321768.
      Citations: 7     Fields:    Translation:Humans
    42. Hansen JM, Sood AK, Coleman RL, Westin SN, Soliman PT, Ramirez PT, Fellman BM, Schmeler KM, Fleming ND. Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer. Gynecol Oncol. 2018 12; 151(3):428-432. PMID: 30366647; PMCID: PMC6281799.
      Citations: 4     Fields:    Translation:Humans
    43. Dood RL, Fleming ND, Coleman RL, Westin SN, Lara OD, LaFargue CJ, Liu J, Sood AK. When Ovarian Cancer Is Not: Characterizing Nonovarian Cancer Pathology in a Laparoscopy-Based Triage System. Int J Gynecol Cancer. 2018 10; 28(8):1485-1490. PMID: 30036226; PMCID: PMC6355335.
      Citations: 2     Fields:    Translation:Humans
    44. Nathenson MJ, Conley AP, Lin H, Fleming N, Lazar A, Wang WL, Ravi V. The Importance of Lymphovascular Invasion in Uterine Adenosarcomas: Analysis of Clinical, Prognostic, and Treatment Outcomes. Int J Gynecol Cancer. 2018 09; 28(7):1297-1310. PMID: 30044322.
      Citations: 3     Fields:    Translation:Humans
    45. Fleming ND, Nick AM, Coleman RL, Westin SN, Ramirez PT, Soliman PT, Fellman B, Meyer LA, Schmeler KM, Lu KH, Sood AK. Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer. Obstet Gynecol. 2018 09; 132(3):545-554. PMID: 30095787; PMCID: PMC6105510.
      Citations: 17     Fields:    Translation:Humans
    46. Gunther JR, Christensen EN, Allen PK, Ramondetta LM, Jhingran A, Fleming ND, Euscher ED, Lu KH, Eifel PJ, Klopp AH. Role of Radiation Therapy in the Multidisciplinary Management of Uterine Carcinosarcoma. Int J Gynecol Cancer. 2018 01; 28(1):114-121. PMID: 28930812.
      Citations: 1     Fields:    Translation:Humans
    47. Dioun SM, Fleming ND, Munsell MF, Lee J, Ramirez PT, Soliman PT. Setting Benchmarks for the New User: Training on the Robotic Simulator. JSLS. 2017 Oct-Dec; 21(4). PMID: 29279661; PMCID: PMC5737239.
      Citations: 1     Fields:    Translation:Humans
    48. Fleming ND, Coleman RL, Tung C, Westin SN, Hu W, Sun Y, Bhosale P, Munsell MF, Sood AK. Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. Gynecol Oncol. 2017 10; 147(1):41-46. PMID: 28774461; PMCID: PMC5605462.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    49. Soliman PT, Westin SN, Dioun S, Sun CC, Euscher E, Munsell MF, Fleming ND, Levenback C, Frumovitz M, Ramirez PT, Lu KH. A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Gynecol Oncol. 2017 08; 146(2):234-239. PMID: 28528918; PMCID: PMC5860676.
      Citations: 36     Fields:    Translation:Humans
    50. Holman LL, Pal N, Iglesias DA, Soliman PT, Balakrishnan N, Klopp A, Broaddus RR, Fleming ND, Munsell MF, Lu KH, Westin SN. Factors prognostic of survival in advanced-stage uterine serous carcinoma. Gynecol Oncol. 2017 07; 146(1):27-33. PMID: 28465008; PMCID: PMC5539404.
      Citations: 12     Fields:    Translation:Humans
    51. Dalton HJ, Fleming ND, Sun CC, Bhosale P, Schmeler KM, Gershenson DM. Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience. Gynecol Oncol. 2017 04; 145(1):37-40. PMID: 28139261; PMCID: PMC5884069.
      Citations: 10     Fields:    Translation:Humans
    52. Suidan RS, He W, Sun CC, Zhao H, Fleming ND, Ramirez PT, Soliman PT, Westin SN, Lu KH, Giordano SH, Meyer LA. Impact of body mass index and operative approach on surgical morbidity and costs in women with endometrial carcinoma and hyperplasia. Gynecol Oncol. 2017 04; 145(1):55-60. PMID: 28131529; PMCID: PMC5557389.
      Citations: 9     Fields:    Translation:Humans
    53. Nathenson MJ, Ravi V, Fleming N, Wang WL, Conley A. Uterine Adenosarcoma: a Review. Curr Oncol Rep. 2016 11; 18(11):68. PMID: 27718181.
      Citations: 20     Fields:    Translation:Humans
    54. Fleming ND, Ramirez PT, Soliman PT, Schmeler KM, Chisholm GB, Nick AM, Westin SN, Frumovitz M. Quality of life after radical trachelectomy for early-stage cervical cancer: A 5-year prospective evaluation. Gynecol Oncol. 2016 Dec; 143(3):596-603. PMID: 27742473; PMCID: PMC5439265.
      Citations: 7     Fields:    Translation:Humans
    55. Brown AJ, Shah JS, Fleming ND, Nick AM, Soliman PT, Chisholm GB, Schmeler KM, Ramirez PT, Frumovitz M. Role of cervical cytology in surveillance after radical trachelectomy for cervical cancer. Gynecol Oncol. 2016 08; 142(2):283-5. PMID: 27246304; PMCID: PMC4961551.
      Citations: 1     Fields:    Translation:Humans
    56. Goldstein J, Pandey P, Fleming N, Westin S, Piha-Paul S. A non-pregnant woman with elevated beta-HCG: A case of para-neoplastic syndrome in ovarian cancer. Gynecol Oncol Rep. 2016 Aug; 17:49-52. PMID: 27355002; PMCID: PMC4910296.
      Citations: 6     
    57. Soliman PT, Westin SN, dos Reis R, Munsell M, Klopp AH, Frumovitz M, Nick AM, Schmeler K, Ramirez PT, Fleming ND. Impact of Lymph Node Ratio and Adjuvant Therapy in Node-Positive Endometrioid Endometrial Cancer. Int J Gynecol Cancer. 2015 Oct; 25(8):1437-44. PMID: 26332387; PMCID: PMC4581897.
      Citations: 8     Fields:    Translation:Humans
    58. Arms RG, Sun CC, Burzawa JK, Fleming ND, Nick AM, Rallapalli V, Westin SN, Meyer LA, Ramirez PT, Soliman PT. Improvement in quality of life after robotic surgery results in patient satisfaction. Gynecol Oncol. 2015 Sep; 138(3):727-30. PMID: 26197762; PMCID: PMC4816594.
      Citations: 6     Fields:    Translation:Humans
    59. Turner TB, Habib AS, Broadwater G, Valea FA, Fleming ND, Ehrisman JA, Di Santo N, Havrilesky LJ. Postoperative Pain Scores and Narcotic Use in Robotic-assisted Versus Laparoscopic Hysterectomy for Endometrial Cancer Staging. J Minim Invasive Gynecol. 2015 Sep-Oct; 22(6):1004-10. PMID: 25967934.
      Citations: 2     Fields:    Translation:Humans
    60. Darin MC, Dalton H, Jhingran A, Fleming N, Brown J, Ramirez PT, G?mez-Hidalgo NR. Ovarian torsion after laparoscopic ovarian transposition in patients with gynecologic cancer: a report of two cases. J Minim Invasive Gynecol. 2015 May-Jun; 22(4):687-90. PMID: 25772021.
      Citations: 2     Fields:    Translation:Humans
    61. Fleming ND, Frumovitz M, Schmeler KM, dos Reis R, Munsell MF, Eifel PJ, Soliman PT, Nick AM, Westin SN, Ramirez PT. Significance of lymph node ratio in defining risk category in node-positive early stage cervical cancer. Gynecol Oncol. 2015 Jan; 136(1):48-53. PMID: 25451695; PMCID: PMC4430191.
      Citations: 40     Fields:    Translation:Humans
    62. Carroll A, Ramirez PT, Westin SN, Soliman PT, Munsell MF, Nick AM, Schmeler KM, Klopp AH, Fleming ND. Uterine adenosarcoma: an analysis on management, outcomes, and risk factors for recurrence. Gynecol Oncol. 2014 Dec; 135(3):455-61. PMID: 25449308; PMCID: PMC4430193.
      Citations: 29     Fields:    Translation:Humans
    63. Ulm MA, Fleming ND, Rallapali V, Munsell MF, Ramirez PT, Westin SN, Nick AM, Schmeler KM, Soliman PT. Position-related injury is uncommon in robotic gynecologic surgery. Gynecol Oncol. 2014 Dec; 135(3):534-8. PMID: 25449565; PMCID: PMC4268144.
      Citations: 4     Fields:    Translation:Humans
    64. Penner KR, Fleming ND, Barlavi L, Axtell AE, Lentz SE. Same-day discharge is feasible and safe in patients undergoing minimally invasive staging for gynecologic malignancies. Am J Obstet Gynecol. 2015 Feb; 212(2):186.e1-8. PMID: 25132462.
      Citations: 5     Fields:    Translation:Humans
    65. Slaughter KN, Frumovitz M, Schmeler KM, Nick AM, Fleming ND, Munsell MF, Westin SN, Soliman PT, Ramirez PT, dos Reis R. Minimally invasive surgery for endometrial cancer: does operative start time impact surgical and oncologic outcomes? Gynecol Oncol. 2014 Aug; 134(2):248-52. PMID: 24945591; PMCID: PMC4286393.
      Citations: 5     Fields:    Translation:Humans
    66. Jones N, Fleming ND, Nick AM, Munsell MF, Rallapalli V, Westin SN, Meyer LA, Schmeler KM, Ramirez PT, Soliman PT. Conversion from robotic surgery to laparotomy: a case-control study evaluating risk factors for conversion. Gynecol Oncol. 2014 Aug; 134(2):238-42. PMID: 24937481; PMCID: PMC4125462.
      Citations: 7     Fields:    Translation:Humans
    67. Clark LH, Soliman PT, Odetto D, Munsell MF, Schmeler KM, Fleming N, Westin SN, Nick AM, Ramirez PT. Incidence of trocar site herniation following robotic gynecologic surgery. Gynecol Oncol. 2013 Nov; 131(2):400-3. PMID: 23988416; PMCID: PMC4158736.
      Citations: 11     Fields:    Translation:Humans
    68. Fleming ND, Ramirez PT. Robotic surgery in gynecologic oncology. Curr Opin Oncol. 2012 Sep; 24(5):547-53. PMID: 22581356.
      Citations: 3     Fields:    Translation:Humans
    69. Fleming ND, Axtell AE, Lentz SE. Operative and anesthetic outcomes in endometrial cancer staging via three minimally invasive methods. J Robot Surg. 2012 Dec; 6(4):337-44. PMID: 27628475.
      Citations: 2     Fields:    
    70. Fleming ND, Agadjanian H, Nassanian H, Miller CW, Orsulic S, Karlan BY, Walsh CS. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer. Cancer. 2012 Feb 01; 118(3):689-97. PMID: 21751198.
      Citations: 20     Fields:    Translation:HumansCells
    71. Barnett JC, Havrilesky LJ, Bondurant AE, Fleming ND, Lee PS, Secord AA, Berchuck A, Valea FA. Adverse events associated with laparoscopy vs laparotomy in the treatment of endometrial cancer. Am J Obstet Gynecol. 2011 Aug; 205(2):143.e1-6. PMID: 21514921.
      Citations: 6     Fields:    Translation:Humans
    72. Fleming ND, Cass I, Walsh CS, Karlan BY, Li AJ. CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol. 2011 May 01; 121(2):249-52. PMID: 21300398.
      Citations: 17     Fields:    Translation:Humans
    73. Fleming ND, Havrilesky LJ, Valea FA, Allen TK, Broadwater G, Bland A, Habib AS. Analgesic and antiemetic needs following minimally invasive vs open staging for endometrial cancer. Am J Obstet Gynecol. 2011 Jan; 204(1):65.e1-6. PMID: 20869036.
      Citations: 3     Fields:    Translation:Humans
    74. Fleming ND, Lentz SE, Cass I, Li AJ, Karlan BY, Walsh CS. Is older age a poor prognostic factor in stage I and II endometrioid endometrial adenocarcinoma? Gynecol Oncol. 2011 Feb; 120(2):189-92. PMID: 21112078.
      Citations: 6     Fields:    Translation:Humans
    75. Secord AA, Havrilesky LJ, O'Malley DM, Bae-Jump V, Fleming ND, Broadwater G, Cohn DE, Gehrig PA. A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer. Gynecol Oncol. 2009 Sep; 114(3):442-7. PMID: 19560193.
      Citations: 31     Fields:    Translation:Humans
    76. Fleming ND, Alvarez-Secord A, Von Gruenigen V, Miller MJ, Abernethy AP. Indwelling catheters for the management of refractory malignant ascites: a systematic literature overview and retrospective chart review. J Pain Symptom Manage. 2009 Sep; 38(3):341-9. PMID: 19328648.
      Citations: 21     Fields:    Translation:Humans
    77. Neubauer NL, Havrilesky LJ, Calingaert B, Bulusu A, Bernardini MQ, Fleming ND, Bland AE, Secord AA. The role of lymphadenectomy in the management of preoperative grade 1 endometrial carcinoma. Gynecol Oncol. 2009 Mar; 112(3):511-6. PMID: 19144394.
      Citations: 16     Fields:    Translation:Humans
    78. Uterine Adenosarcoma. Current Oncology Reports. 18.
    79. Impact of lymph node ratio and adjuvant therapy in node-positive endometrioid endometrial cancer. International Journal of Gynecological Cancer. 25:1437-1444.
    80. Fertility Preservation in the Gynecologic Cancer Patient. 469-485.
    81. Role of cervical cytology in surveillance after radical trachelectomy for cervical cancer. Gynecologic Oncology.
    82. Erratum. Cancer. 118:5450.
    83. Operative and anesthetic outcomes in endometrial cancer staging via three minimally invasive methods. Journal of Robotic Surgery. 6:337-344.
    84. A non-pregnant woman with elevated beta-HCG. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. 17:49-52.
    85. Quality of life after radical trachelectomy for early-stage cervical cancer. Gynecologic Oncology. 143:596-603.
    FLEMING's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (259)
    Explore
    _
    Co-Authors (71)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _